Stockscreener 앱 받기
0.5201
1.48%
-0.0078
시간 외 거래:
.53
0.0099
+1.90%
전일 마감가:
$0.5279
열려 있는:
$0.53
하루 거래량:
1.59M
Relative Volume:
1.27
시가총액:
$62.39M
수익:
-
순이익/손실:
$-225.14M
주가수익비율:
-0.2654
EPS:
-1.96
순현금흐름:
$-192.27M
1주 성능:
-26.45%
1개월 성능:
-31.57%
6개월 성능:
-70.62%
1년 성능:
-40.77%
1일 변동 폭
$0.5031
$0.55
1주일 범위
$0.483
$0.7192
52주 변동 폭
$0.3546
$2.74
Invivyd Inc Stock (IVVD) Company Profile
명칭
Invivyd Inc
전화
(781) 819-0080
주소
1601 TRAPELO ROAD, WALTHAM
IVVD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
0.5201 | 69.71M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-05 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-03-26 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | 개시 | H.C. Wainwright | Buy |
Invivyd Inc 주식(IVVD)의 최신 뉴스
Exit strategy if you’re trapped in Invivyd Inc.Gold Moves & Low Drawdown Trading Strategies - Newser
Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Invivyd prices $50 million public offering at $0.52 per share - Investing.com
$50 Million Capital Raise: Invivyd Secures Funding for Long COVID and RSV Research Programs - Stock Titan
Invivyd prices public offering at $0.52 per share - MarketScreener
Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire Inc.
Will Invivyd Inc. stock go up soon2025 Earnings Surprises & Verified High Yield Trade Plans - Newser
Invivyd announces public offering of common stock - Investing.com
Invivyd announces proposed public offering of common stock - MarketScreener
Invivyd Announces Proposed Public Offering of Common Stock - MarketScreener
Clinical-Stage Biotech Invivyd Announces Stock Offering to Advance COVID, RSV Pipeline Programs - Stock Titan
Invivyd, Inc. Stock (IVVD) Opinions on Q2 2025 Earnings and Insider Selling - Quiver Quantitative
Trend analysis for Invivyd Inc. this weekJuly 2025 WrapUp & Free Technical Pattern Based Buy Signals - Newser
Understanding Invivyd Inc.’s price movement2025 Price Action Summary & AI Driven Price Predictions - Newser
Order flow analysis tools used on Invivyd Inc.Market Activity Recap & Long-Term Growth Portfolio Plans - Newser
How to monitor Invivyd Inc. with trend dashboardsCEO Change & Smart Swing Trading Alerts - Newser
Invivyd (IVVD) chief scientific officer Allen sells $27k in stock - Investing.com
Invivyd Inc. stock daily chart insightsJuly 2025 Highlights & Reliable Breakout Forecasts - Newser
What makes Invivyd Inc. stock price move sharplyJuly 2025 Weekly Recap & Free Community Consensus Stock Picks - beatles.ru
Invivyd Analyst Reviews: A Comprehensive Look at Ratings and Price Targets - AInvest
Invivyd Analyst Reiterates 'Buy' Rating and Price Target at $3.00 - AInvest
Invivyd: Boral Capital Raises PT to $3, Maintains Buy Rating - AInvest
Invivyd stock maintains Buy rating at H.C. Wainwright on VYD2311 path - Investing.com
What machine learning models say about Invivyd Inc.CEO Change & Low Risk High Win Rate Stock Picks - Newser
Invivyd's Breakthrough Year: Analyst Reiterates Buy Rating Amid Regulatory Advancements and Market Potential - AInvest
Retail Chatter Surges Around Invivyd After Data Show Pemgarda Neutralizes XFG COVID-19 Variant - Asianet Newsable
Invivyd’s PEMGARDA shows continued neutralizing activity against XFG variant By Investing.com - Investing.com Nigeria
Invivyd Says Pemgarda Shows Neutralizing Activity Against SARS-CoV-2 Variant XFG - MarketScreener
Invivyd’s PEMGARDA shows continued neutralizing activity against XFG variant - Investing.com
Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG ('Stratus”) - The Manila Times
Invivyd's PEMGARDA (pemivibart) Demonstrates Continued Neutralizing Activity Against Dominant SARS-CoV-2 Variant XFG and Multiple Other Circulating Variants. - AInvest
COVID Wave Rising: Invivyd's PEMGARDA Proves Effective Against New XFG "Stratus" Variant in 34 States - Stock Titan
Relief Rally in Invivyd Inc. Stock — Can It HoldJuly 2025 Spike Watch & Verified High Yield Trade Plans - metal.it
Invivyd’s Transformative Year: Regulatory Advances and Market Potential Drive Buy Rating - TipRanks
Invivyd Q2 2025 slides: Revenue growth amid missed profitability target - Investing.com
Invivyd Q2 2025 Earnings Miss Sparks Investor Concerns - AInvest
Senior Manager/Associate Director, Marketing Waltham/Bostonwill consider remo at Invivyd - Mediabistro
Invivyd Posts Q2 2025 Earnings Miss with Sustained Market Pressure - AInvest
Why is Invivyd Inc. stock going upTrade Ideas & AI Forecasted Stock Moves - thegnnews.com
Measuring Invivyd Inc.’s beta against major indicesJuly 2025 Rallies & Target Return Focused Stock Picks - Newser
Why Invivyd Inc. stock attracts strong analyst attentionJuly 2025 WrapUp & Long-Term Safe Return Strategies - Newser
Why Invivyd's Earnings Miss Masks a High-Conviction Long-Term Play in Monoclonal Antibody Innovation - AInvest
Invivyd Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Invivyd Secures FDA Approval for Streamlined Approval Pathway of COVID-19 Monoclonal Antibody VYD2311 - AInvest
Invivyd Stock: Analyst Lowers Price Target to $3.00, Maintains 'Buy' Rating - AInvest
Invivyd Inc Q2 2025 Earnings: Revenue Surges, Earnings Miss Estimates - AInvest
Pediatrix Medical Group, Inc. shares rise 2.77% intraday after Invivyd's FDA alignment for VYD2311 COVID-19 vaccine. - AInvest
Invivyd, Inc. shares fall 11.51% intraday despite FDA alignment on rapid pathway for VYD2311. - AInvest
Invivyd: Boral Capital Maintains Buy Rating, PT Down to $3 from $9 - AInvest
Alignment Healthcare shares rise 1.89% premarket after Invivyd aligns with FDA on rapid pathway for COVID-19 vaccine alternative. - AInvest
Canopy Growth Corporation shares rise 5.37% premarket after Invivyd's FDA alignment on rapid pathway for COVID-19 vaccine alternative. - AInvest
Invivyd Inc (IVVD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Invivyd Inc 주식 (IVVD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lee Timothy Edward | Chief Commercial Officer |
Aug 18 '25 |
Sale |
0.65 |
20,013 |
13,012 |
88,987 |
| Duke William E. | Chief Financial Officer |
Aug 19 '25 |
Sale |
0.57 |
29,643 |
16,796 |
49,344 |
| Duke William E. | Chief Financial Officer |
Aug 18 '25 |
Sale |
0.65 |
20,013 |
13,012 |
78,987 |
| Green Julie | Chief Human Resources Officer |
Aug 19 '25 |
Sale |
0.57 |
29,643 |
16,796 |
49,344 |
| Green Julie | Chief Human Resources Officer |
Aug 18 '25 |
Sale |
0.65 |
20,013 |
13,012 |
78,987 |
| Andersen Jill | Chief Legal Officer, Secretary |
Aug 19 '25 |
Sale |
0.57 |
49,402 |
27,991 |
84,446 |
| Andersen Jill | Chief Legal Officer, Secretary |
Aug 18 '25 |
Sale |
0.65 |
33,352 |
21,685 |
133,848 |
| Allen Robert D. III | Chief Scientific Officer |
Aug 19 '25 |
Sale |
0.57 |
27,420 |
15,536 |
53,068 |
| Allen Robert D. III | Chief Scientific Officer |
Aug 18 '25 |
Sale |
0.65 |
18,512 |
12,037 |
80,488 |
0.94%
1.72%
자본화:
|
볼륨(24시간):